vTv Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated June 1, 2022, covers the results of vTv Therapeutics Inc.'s 2022 Annual Meeting of Stockholders. The company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol VTVT.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Director Elections: Stockholders elected five nominees to the Board of Directors for terms expiring at the 2023 annual meeting. All nominees received significant "For" votes, ranging from approximately 50.96 million to 51.27 million. Broker non-votes totaled 23,385,206 for each nominee.
- Appointment of Auditors: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022. The vote was 75,002,603 "For," 192,170 "Against," and 131,987 "Abstain."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the annual meeting votes.
Key Facts for Investor Verification
- Confirmation that all five director nominees were successfully elected.
- Verification of the ratification of Ernst & Young LLP as the independent auditor.
- Review of the total number of shares represented at the meeting, indicated by the sum of votes cast and broker non-votes.
- Confirmation of Richard S. Nelson's role as Interim Chief Executive Officer, as indicated in the signature block.